Zota Health Care LimitedQ2 FY27 Results & Financial Update
Zota Health Care Limited: Q2 FY27 consolidated results and company financials – revenue ₹199.33 Cr, PAT ₹-25.96 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Zota Health Care price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Zota Health Care Q2 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
During the second quarter of fiscal 2027, Zota Health Care reported consolidated revenue from operations of INR 199.33 crore, reflecting a sequential expansion compared to INR 173.60 crore in the preceding quarter ended June 30, 2026.
Total consolidated income for Q2 FY27 rose to INR 204.19 crore, supported by other income of INR 4.86 crore, compared to total income of INR 175.65 crore reported in Q1 FY27.
Despite the growth in top-line figures, the group recorded a wider net loss for the period. Consolidated loss before tax stood at INR 27.10 crore, deepening from a PBT loss of INR 43.65 crore in Q1 FY27.
Consolidated net profit after tax (PAT) for the quarter was reported at a loss of INR 25.96 crore, compared to a net loss of INR 43.94 crore in the previous quarter.
Basic and diluted earnings per share (EPS) for Q2 FY27 stood at negative INR 7.39, compared to negative INR 12.58 in the first quarter of the fiscal year.
The bottom line was significantly weighed down by elevated purchases of stock-in-trade at INR 100.71 crore, employee benefit expenses of INR 70.17 crore, and notable provisions totaling INR 43.96 crore recognized during the quarter.
Finance costs remained steady at INR 6.36 crore, while depreciation and amortization expenses were reported at INR 28.66 crore for the quarter.
01 · Business model
What does Zota Health Care do?
Zota Health Care Limited is a pharmaceutical and healthcare company engaged in the manufacturing, marketing, and retail distribution of diverse pharmaceutical formulations, generic medicines, and wellness products.
The company operates its manufacturing facility located at the Surat Special Economic Zone (SEZ) in Gujarat and manages its extensive commercial activities through a network of domestic and international subsidiaries.
Its business model integrates product development, institutional and trade distribution, and specialized retail health marts, enabling broad market reach across both domestic and overseas channels.
02 · Financial snapshot
Current quarter vs the available comparable
| Metric | Q2 FY27 | Previous quarter |
|---|---|---|
| Revenue from operations | ₹199.33 Cr | ₹173.60 Cr |
| Total income | ₹204.19 Cr | ₹175.65 Cr |
| Profit before tax | ₹-27.10 Cr | ₹-43.65 Cr |
| Profit after tax | ₹-25.96 Cr | ₹-43.94 Cr |
| EPS | ₹-7.39 | ₹-12.58 |
Financial interpretation
What the reported numbers mean
Profit after tax represented -13.0% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to -13.6% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹4.86 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
Consolidated revenue from operations increased to INR 199.33 crore in Q2 FY27 from INR 173.60 crore in Q1 FY27, demonstrating continued top-line demand across operating segments.
Other income contributed INR 4.86 crore to the total consolidated income of INR 204.19 crore during the quarter.
What drove margins
High purchases of stock-in-trade amounting to INR 100.71 crore and employee benefit expenses of INR 70.17 crore exerted substantial pressure on consolidated margins.
Depreciation and amortization expenses stood at INR 28.66 crore, while the adoption of Ind AS 116 for leases resulted in a recognized right-of-use asset and corresponding lease liabilities impacting period profitability by INR 1.93 crore.
04 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
In accordance with Ind AS 108, the company evaluated its operating segments and concluded that it operates in a single primary business segment.
05 · Strategy & new businesses
How the company is trying to change its growth mix
During the quarter, the company invested INR 119.52 crore by subscribing to 235,512 equity shares of its wholly-owned subsidiary, Davaindia Health Mart Limited, on a preferential basis via the conversion of outstanding unsecured loans and accumulated interest.
06 · Reported developments
What changed operationally
Quarterly operating revenue increased sequentially to INR 199.33 crore from INR 173.60 crore in the preceding quarter.
07 · Pressure points & risks
What is not going smoothly
The company reported a consolidated net loss of INR 25.96 crore for Q2 FY27, driven by high operating expenses and provisions.
08 · Items worth noticing
The line items that can distort a quick read
The company recognized provisions amounting to INR 43.96 crore during the quarter.
09 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Capital allocation & funding
As of September 30, 2026, consolidated non-current borrowings stood at INR 6.53 crore, while current borrowings were reported at INR 25.50 crore.
10 · Beyond the numbers
What changed beyond the numbers
Reported update
Auditor Review
Statutory auditors Pradeep K. Singhi & Associates carried out a limited review of the standalone and consolidated financial results for Q2 FY27 with an unmodified review conclusion.
11 · Previous-quarter changes
What changed since the previous quarter
Consolidated profit before tax improved from a loss of INR 43.65 crore in Q1 FY27 to a loss of INR 27.10 crore in Q2 FY27.
12 · Key Q&A
The quarter, answered directly
What does Zota Health Care do?
Zota Health Care Limited is a pharmaceutical and healthcare company engaged in the manufacturing, marketing, and retail distribution of diverse pharmaceutical formulations, generic medicines, and wellness products.
What is the clearest takeaway from Q2 FY27?
During the second quarter of fiscal 2027, Zota Health Care reported consolidated revenue from operations of INR 199.33 crore, reflecting a sequential expansion compared to INR 173.60 crore in the preceding quarter ended June 30, 2026.
What drove revenue or demand?
Consolidated revenue from operations increased to INR 199.33 crore in Q2 FY27 from INR 173.60 crore in Q1 FY27, demonstrating continued top-line demand across operating segments.
What mattered most for margins or profitability?
High purchases of stock-in-trade amounting to INR 100.71 crore and employee benefit expenses of INR 70.17 crore exerted substantial pressure on consolidated margins.
What changed operationally beyond the headline numbers?
During the quarter, the company invested INR 119.52 crore by subscribing to 235,512 equity shares of its wholly-owned subsidiary, Davaindia Health Mart Limited, on a preferential basis via the conversion of outstanding unsecured loans and accumulated interest.
What are the main pressure points disclosed for the quarter?
The company reported a consolidated net loss of INR 25.96 crore for Q2 FY27, driven by high operating expenses and provisions.
13 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
14 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Operational Turnaround: Monitor future quarters for cost rationalization and potential margin recovery across consolidated subsidiaries.
- 02
Subsidiary Scaling: Track the commercial progress and financial performance of key subsidiaries such as Davaindia Health Mart Limited following recent capital injections.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.